Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShuYangMinNing plus loratadine for chronic spontaneous urticaria
ChiCTR2400081126Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of histaglobulin and loratadine in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease control rate during the last week of treatment. Started Oct 2023; status: completed.
02
Drugs
histaglobulinloratadine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on ChiCTR2400081126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081126.